All In Biotech

Investigational drug · Phase 2

Tominersen

Also called: RO7234292, RG6042

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Huntington Disease.

Phase 2

Last checked: Nov 19, 2026Latest source record: Aug 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

5

Any phase or sponsor naming "Tominersen"

First trial start

2023

Feb 3, 2023

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Tominersen", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Huntington Disease

Approved drugs for the same conditions: Huntington's disease chorea · Neurology

Largest trials

Live from ClinicalTrials.gov: studies naming "Tominersen" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 28 on PubMed

Also in development for Huntington Disease

  • SKY-0515Phase 33 trials

    Skyhawk Therapeutics, Inc. · Huntington Disease, Huntingtons Disease, Huntington's Disease (HD)

  • PridopidinePhase 32 trials

    Prilenia · Amyotrophic Lateral Sclerosis, Huntington Disease

  • ER2001Phase 21 trial

    ExoRNA Bioscience · Huntington Disease

  • MBF-015Phase 21 trial

    Medibiofarma S.L. · Huntington Disease

  • VO659Phase 21 trial

    Vico Therapeutics B. V. · Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 3, Huntington Disease

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Roche (Genentech).

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.